Xcout IntelDianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Subscribe to see Dianthus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Dianthus Therapeutics, Inc. at a glance
Dianthus Therapeutics, Inc. is a biotechnology company headquartered in New York, United States. It is publicly listed (DNTH) with a market capitalisation of $4.6B. Xcout tracks 18 named people at Dianthus Therapeutics, Inc., including Marino Garcia (President, Chief Executive Officer & Director). Xcout recorded 15 job postings from Dianthus Therapeutics, Inc. in the last 90 days.
Dianthus Therapeutics, Inc. leadership
- Marino GarciaPresident, Chief Executive Officer & Director
- Ryan SavitzExecutive VP, CFO, Chief Business Officer & Treasurer
- Edward G. CarrSenior VP & Chief Accounting Officer
- Kristina MaximenkoChief People Officer
- Simrat RandhawaExecutive Vice President and Head of R&D
- Adam VenessSenior Vice President, General Counsel & Secretary
12 more named people on record for Dianthus Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Dianthus Therapeutics, Inc.
Xcout recorded 15 job postings from Dianthus Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Dianthus Therapeutics, Inc.'s hiring signals →
Investors
Dianthus Therapeutics, Inc. competitors
A few of Dianthus Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Cyxone AB is a clinical-stage biotechnology company headquartered in Malmö, Sweden. It focuses on developing a new generation of disease-modifying therapies for autoimmune and autoinflammatory diseases.
Artax Biopharma, Inc. is a clinical-stage biotechnology company founded in 2013 and headquartered in Cambridge, Massachusetts. The company is focused on transforming the treatment of immune system diseases and recently raised $8 million ahead of a Phase 2a clinical trial.
Enthera is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Milan, Italy. The company focuses on developing first-in-class therapeutics for auto-immune disorders and is backed by investors such as Sofinnova Partners and BiovelocITA.
Get Dianthus Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Dianthus Therapeutics, Inc. in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access